My early scientific training and publications came from my PhD. work where I focused on the study of various microbial triggers, with special emphasis on Helicobacter pylori and Epstein-Barr virus (EBV) implicated in the development of gastroduodenal cancer. Besides my thesis work, I was also involved in other projects, in which I evaluated the certain multi drug resistant organisms at molecular level such as VRE, MRSA, NDM-1 and KPC producing gram negatives. During my post-doctoral training (2013-2020), I studied the genetic, proteomic, and biochemical approaches to identify viral pathways to induce cell mediated growth transformation. I explored the immunotherapeutic agents (vaccine, checkpoint inhibitors) combined with conventional treatment modalities (radiation/targeted agents) to enhance anti-tumor effects in virus associated cancer. I also got opportunity to learn inflammation as a means to identify promising new targets to treat patients with diabetes. That filed was little different from my previous experience however, it encouraged me to learn the translational research linked with metabolic diseases.  Currently, I am exploring the gut microbiome modification based therapeutic approach for cancer and metabolic diseases. Moreover, I am also exploring different natural product as an immunotherapeutic agent against virus associated cancers. I am also engaged in evaluating in-vitro in-vivo anticancer/antiviral potential of natural and semi-synthetic natural products.